Guerbet Announces ACR Committee on Drugs and Contrast Media Classifies Elucirem (Gadopiclenol) Injection a Group II Agent
Elucirem, a novel new macrocyclic GBCA for use in contrast-enhanced magnetic resonance imaging (MRI), has the highest relaxivity compared to other non-specific GBCAs (gadolinium-based contrast agents)
Source: itnonline.com